ONCOLOGY Vol 38, Issue 1
Tiragolumab Plus Atezolizumab Will Not Be Pursued in Further Cervical Cancer Management
January 12th 2024ArticleInterview
Ritu Salani, MD, MBA, discussed the results from the phase 2 SKYSCRAPER-4 trial, which determined tiragolumab plus atezolizumab should not be used to treat PD-L1–positive recurrent cervical cancer.
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy
Sonia La Spina;Paolo Scollo, MD;Basilio Pecorino, MD;Valentina Lombardo;Annamaria Motta;Rosa Gioia Calderone, MD;Stefania Calì, MD;Helga Maria Alessandra Lipari, MD;Giuseppa Scandurra, MD
January 11th 2024ArticleOriginal Research
A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Building Efficiency and Scaling With a Remote Genetic Counseling Program
Smita K. Rao, MBBS, MS;L. Johnetta Blakely, MD;Kate Small, MS;Stephen Schleicher, MD, MBA;Natalie R. Dickson, MD
January 10th 2024ArticleOriginal Research
Smita K. Rao, MBBS, MS, et al gave an overview of implementing genetic counseling into oncology practices through telemedicine.
